Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 54

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 54
---
 link between the Company’s performance and named executive officer pay and the Compensation Committee did not consider the disclosure below in making its pay decisions for any of the years shown. For further information regarding our compensation, refer to “Executive Compensation.” Required Tabular Disclosure of Pay Versus Performance The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” (or “CAP”) is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals for the fiscal years listed below.

| Year |     |         Summary 
    Compensation 
 Table Total for 
   our PEO(1)(2) 
             ($) |     |     Compensation 
 Actually Paid to 
        PEO(1)(3) 
              ($) |     |         Average 
         Summary 
    Compensation 
 Table Total for 
         Non-PEO 
      NEOs(1)(2) 
             ($) |     |       Average 
  Compensation 
 Actually Paid 
    to Non-PEO 
    NEOs(1)(3) 
           ($) |     | Value of Initial 
       Fixed $100 
       Investment 
   Based On Total 
      Stockholder 
           Return 
       (“TSR”)(4) 
              ($) |     |    Net Income 
    (Loss) (in 
 thousands)(5) 
           ($) |
| 2024 |     |       5,648,201 |     |       31,241,665 |     |       5,047,863 |     |     8,683,305 |     |           218.55 |     |      -152,148 |
| 2023 |     |       3,429,733 |     |        1,986,784 |     |       1,391,247 |     |     1,437,499 |     |            79.48 |     |       -95,990 |

| (1) | The following individuals are our PEO and other Non-PEO NEOs for each fiscal year: |

| Year |     | PEO                    |     | Non-PEO NEOs      |
| 2024 |     | Marshall Fordyce, M.D. |     |